The ICER review is in: hope amidst uncertainty.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 34949117.
- Also identified by DOI 10.18553/jmcp.2022.28.1.115 and PMC identifier 10373011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<b>DISCLOSURES:</b> No funding contributed to the writing of this commentary. Smith Begolka, Butler, and Guadalupe are salaried employees of the National Eczema Association, which has received grants and sponsorship awards from a variety of industry partners, including AbbVie, Eli Lilly, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi. Smith Begolka has received grant funding from Pfizer and advisory board honoraria from Pfizer and Incyte. Butler and Guadalupe have received advisory board honoraria from Incyte.
Medical subject headings
- Dermatitis, Atopic
- Uncertainty